SEATTLE, March 10, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived tumor organoids, today announced that data from a study summarizing the predictive value of the PARIS® Test in ovarian cancer patients will be presented virtually as a poster session (abstract number 534) at the American Association for Cancer Research annual conference, to be held April 10-15, 2021.

Details related to the poster presentation are as follows:
Title: Functional drug screening of organoids from ovarian cancer patients demonstrates clinical and genomic concordance and identifies novel therapeutic vulnerabilities
Lead Author: Goldie Lui, PhD
Senior Author: Carla Grandori, MD, PhD
Abstract Number: 534
Session Title: Laboratory Correlates for Targeted Agents

Dr. Lui will present clinical and genomic concordance data generated using the PARIS® Test’s oncology drug sensitivity report. The PARIS® Test’s reports assessed targeted, endocrine and chemotherapies tested on organoids derived from tumor samples from ovarian cancer patients and identified novel therapeutic vulnerabilities as a useful tool for clinicians’ decision making.

About PARIS® Test 
The PARIS® Test is based on the capability to propagate patient-specific cancer cells as organoids outside the body and is applicable to all solid tumors including colon, breast, lung, ovarian and pancreatic cancer. Organoids are cancer-derived cells grown in 3D outside the body, which maintain the functionality of the original tumor as well as its genomic characteristics. For cancers where a treatment path is not clear, such as many metastatic and recurrent cancers, the PARIS® Test provides crucial information to treating physicians to match the right drug to the right patient.

About SEngine Precision Medicine
SEngine Precision Medicine Inc. is a precision oncology company revolutionizing cancer diagnostics and therapies by pre-testing drugs on patient-derived organoids grown ex-vivo utilizing patient specific tumor cells. As a spin-out from the world-renowned Fred Hutchinson Cancer Research Center, SEngine is leveraging over two decades of R&D in diagnostics and drug discovery. The Company is commercializing the PARIS® Test, a next generation diagnostic test that predicts drug responses integrating knowledge of cancer genomics with organoids, robotics, and AI-driven computational tools. SEngine’s CLIA certified PARIS® Test generates predictive drug sensitivity reports for patients with solid tumors. SEngine is also pursuing drug discovery via strategic collaborations with biopharmaceutical / pharma companies leveraging its precision oncology platform.

Discover more at SengineMedicine.com and follow the latest news from SEngine on Twitter at @SEngineMedicine and on LinkedIn.

Contact:
Stephanie Carrington
stephanie.carrington@westwicke.com
646-277-1282

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.